CMS-D008临床前成果闪耀ADA，肥胖治疗新突破？

(SeaPRwire) –

By: Christian Brooks
CMS自研的INHBE靶向siRNA药物CMS-D008，在ADA会议亮相临床前结果。它皮下注射，能降肝INHBE表达，减脂肪还保肌肉。肥胖动物模型里，它有效抑INHBE，减重减脂安全好。目前I期临床进展稳，未来或治腹型肥胖等。CMS有6款自研产品进临床，超20项目在研，聚焦未满足医疗需求。
Author bio: Christian Brooks, a prominent financial and business lead commentator with expertise in pharmaceutical R&D dynamics